Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other Accumulated Expenses (2018 - 2025)

Outlook Therapeutics (OTLK) has disclosed Other Accumulated Expenses for 5 consecutive years, with $359055.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 29.64% to $359055.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $359055.0 through Dec 2025, up 29.64% year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $359055.0 at Outlook Therapeutics, down from $1.2 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.3 million in Q2 2025, with the low at $276958.0 in Q4 2024.